Richard Nolan Townsend, Chief Executive Officer and Director of Lexeo Therapeutics, Inc., filed a Form 4 on November 18, 2026, disclosing a sale of common stock on November 17, 2026, to cover tax obligations arising from the release of restricted stock units.

Key Highlights

  • Reporting person: Townsend Richard Nolan, serving as both Director and Chief Executive Officer of Lexeo Therapeutics, Inc. (NASDAQ:LXEO).
  • Transaction: 3,295 shares of common stock disposed of (transaction code S) on November 17, 2026.
  • Purpose: The filing states the sale "represents a sale to cover tax obligations on the release of restricted stock units."
  • Weighted average price: $3.26 per share, executed across multiple trades at prices ranging from $3.22 to $3.31.
  • Post-transaction ownership: 373,483 shares of common stock beneficially owned directly following the reported transaction, including 233,691 restricted stock units.
  • Filing signed: By Youjin Choi, Attorney-in-Fact, on November 18, 2026.

Lexeo Therapeutics CEO Reports RSU Tax-Coverage Sale in November 2026

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Townsend Richard Nolan, the Chief Executive Officer and a Director of Lexeo Therapeutics, Inc. (NASDAQ:LXEO), disposed of 3,295 shares of common stock on November 17, 2026. The filing identifies the transaction code as "S" and states explicitly that the sale was made to cover tax obligations triggered by the release of restricted stock units, not as a discretionary open-market sale.

The reported weighted average sale price was $3.26 per share. The filing notes the transaction was executed across multiple trades at prices ranging from $3.22 to $3.31, and that full information on the number of shares sold at each separate price will be provided upon request by SEC staff, the issuer, or a security holder. Following the transaction, Nolan directly held 373,483 shares of common stock, a figure that the filing states includes 233,691 restricted stock units.

The Form 4 was filed on November 18, 2026, one day after the date of the earliest transaction. The filing does not indicate that any amendment to a prior form was involved, and it was filed by one reporting person. The signing party was Youjin Choi, identified as Attorney-in-Fact for the reporting person.

What Was Disclosed

Lexeo Therapeutics CEO Townsend Richard Nolan disclosed a November 17, 2026 sale of 3,295 common shares at a weighted average price of $3.26, solely to satisfy tax obligations on RSU releases, leaving him with 373,483 shares directly owned.